Differential Diagnoses for M-Spike in Beta-2 Globulin Region with Free Lambda Light Chains

Primary Differential Diagnoses to Exclude

The International Myeloma Society recommends evaluating for CRAB criteria (hypercalcemia, renal insufficiency, anemia, bone lesions) to distinguish symptomatic multiple myeloma from monoclonal gammopathy of undetermined significance (MGUS) 2, 3
The presence of abnormal free lambda light chains in urine significantly increases concern for progression beyond MGUS, according to the National Comprehensive Cancer Network 4, 5
The American Society of Clinical Oncology suggests that the SLiM criteria (≥60% bone marrow plasma cells, involved:uninvolved free light-chain ratio >100, or >1 bone lesion on MRI) are also diagnostic for multiple myeloma 1, 2
Smoldering multiple myeloma is defined by M-protein ≥30 g/L and/or bone marrow plasma cells 10-60% without CRAB features, with a median time to progression of 2-3 years, as stated by the International Myeloma Society 1, 2, 3

The Mayo Clinic recommends bone marrow biopsy with plasma cell percentage and flow cytometry to quantify clonal burden, as well as complete blood count, comprehensive metabolic panel, and quantitative serum free light chains with kappa/lambda ratio 2, 3, 4, 5
The National Comprehensive Cancer Network suggests that skeletal survey or whole-body low-dose CT should be performed to detect lytic bone lesions, and MRI or PET-CT if focal lesions are suspected 2, 3, 5

The Mayo Clinic model identifies three independent risk factors for progression: M-protein ≥15 g/L, non-IgG isotype (IgA or IgM), and abnormal serum free light-chain ratio, with a risk of progression at 20 years of 5% for zero risk factors, 21% for one risk factor, 37% for two risk factors, and 58% for three risk factors 4, 5, 8

The American Society of Clinical Oncology warns against misattributing organ dysfunction to the monoclonal protein without proper evaluation, and recommends considering alternative causes of renal insufficiency, anemia, and hypercalcemia 3
The International Myeloma Society emphasizes the importance of not dismissing renal dysfunction as unrelated to the monoclonal protein without proper evaluation, as even small M-spikes can cause significant kidney damage through deposition 1, 2
The National Comprehensive Cancer Network suggests that substantial albuminuria with heart failure, neuropathy, or hepatomegaly in the setting of monoclonal protein should trigger evaluation for AL amyloidosis 3, 6